Are you triple negative? Do you have a link to the trial?
I found this:
1: Expert Opin Investig Drugs. 2009 Sep;18(9):1375-83.
Links
Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agent.
Hanson BE,
Vesole DH.
Loyola University Chicago, Stritch School of Medicine, Division of Hematology/Oncology, Department of Medicine, 2160 S 1st Avenue Maywood, IL 60153, USA.
Heat shock proteins are vital to cell survival under conditions of stress. They bind client proteins to assist in protein stabilization, translocation of polypeptides across cell membranes and recovery of proteins from aggregates. Heat shock protein inhibitors are a diverse group of novel agents that have been demonstrated to have pro-apoptotic effects on malignant cells through inhibition of ATP binding on the ATP/ADP-binding pocket of the heat shock protein. Initial development of heat shock protein 90 inhibitors, geldanamycin and 17-AAG, were limited by hepatotoxicity and the need for solvent carrying agents. In contrast, retaspimycin, or IPI-504, a derivative of geldanamycin and 17-AAG, is highly soluble in water and generally well tolerated. In Phase I/II trials, retaspimycin has shown activity in NSCLC and gastrointestinal stromal tumor. The most promising activity was observed in gastrointestinal stromal tumors. Phase I/II trials are currently underway to evaluate the dosing schedules and activity of IPI-504 in breast cancer. Given the in vitro activity in diffuse large B-cell lymphoma, mantle cell lymphoma, melanoma, leukemia and pancreatic cancer, current and future trials are of clinical interest. This article reviews IPI-504 and its utility in a wide variety of cancer phenotypes.
PMID: 19642950 [PubMed - in process
Also..
If you or others are interested in a Taxane that can work against Taxol/Taxotere resistant cancer, there may be a trial for Tesetaxel:
http://www.medicalnewstoday.com/articles/135629.php
Threaded Mode